RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment

Immunotherapy has improved the prognosis for many melanoma patients; however, our capacity to predict patient responses and to understand the biological differences between patients who will or will not respond is limited. Gene expression profiling of tumors from patients who respond to immunotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqui, Jalal, Miles, Wayne O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363879/
https://www.ncbi.nlm.nih.gov/pubmed/34388693
http://dx.doi.org/10.1016/j.tranon.2021.101197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363879/
https://www.ncbi.nlm.nih.gov/pubmed/34388693
http://dx.doi.org/10.1016/j.tranon.2021.101197

Ejemplares similares